Kestra Private Wealth Services LLC Sells 740 Shares of Sanofi (NASDAQ:SNY)

Kestra Private Wealth Services LLC cut its stake in shares of Sanofi (NASDAQ:SNY) by 3.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,864 shares of the company’s stock after selling 740 shares during the period. Kestra Private Wealth Services LLC’s holdings in Sanofi were worth $1,046,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Willner & Heller LLC increased its position in shares of Sanofi by 15.1% in the first quarter. Willner & Heller LLC now owns 6,109 shares of the company’s stock worth $339,000 after purchasing an additional 800 shares during the last quarter. Pzena Investment Management LLC bought a new position in shares of Sanofi in the first quarter worth approximately $299,000. Bailard Inc. increased its position in shares of Sanofi by 69.5% in the first quarter. Bailard Inc. now owns 27,736 shares of the company’s stock worth $1,538,000 after purchasing an additional 11,377 shares during the last quarter. Verdence Capital Advisors LLC increased its position in shares of Sanofi by 11.8% in the first quarter. Verdence Capital Advisors LLC now owns 34,546 shares of the company’s stock worth $1,916,000 after purchasing an additional 3,637 shares during the last quarter. Finally, Legacy Capital Wealth Partners LLC increased its position in shares of Sanofi by 11.6% in the first quarter. Legacy Capital Wealth Partners LLC now owns 13,563 shares of the company’s stock worth $752,000 after purchasing an additional 1,406 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SNY. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, Guggenheim reissued a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $61.50.

Sanofi Trading Up 2.9%

Shares of NASDAQ:SNY opened at $50.16 on Thursday. The stock has a market capitalization of $123.02 billion, a price-to-earnings ratio of 17.91, a PEG ratio of 1.11 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The stock’s 50-day simple moving average is $49.58 and its two-hundred day simple moving average is $52.10. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion for the quarter, compared to analysts’ expectations of $9.79 billion. During the same period in the previous year, the firm earned $1.78 EPS. The business’s quarterly revenue was down 11.0% on a year-over-year basis. Analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.